Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy

NCT06510868 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT06510868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06510868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy
Lead sponsor
University Health Network, Toronto
Phase
Observational
Overall status
Recruiting
Start date
August 1, 2024
Completion date
June 30, 2029
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic syndrome